What was tested?
Check whether the source studied ProGo, another salmon hydrolysate, or finished triGLP.
The short answer
There is a real evidence trail concerning salmon-protein hydrolysates and the ProGo ingredient. ORYGN also publishes regulatory and commercial information about ProGo. That does not automatically mean every finding from an ingredient study applies unchanged to the dose, delivery format or outcomes of finished triGLP drops.
The most important distinction: ingredient evidence can support why an ingredient is of interest. Finished-product evidence is needed to establish what the product itself does at its marketed dose and formulation.
Four different evidence questions
Who was studied?
Population, health status, sample size and study duration affect how widely a result can be applied.
Was the dose comparable?
A result at one dose or format should not be assumed for a different dose or sublingual product.
How to read the available sources
| Source | What it supports | What it does not establish by itself |
|---|---|---|
| ORYGN triGLP page | Official product format, brand positioning and ORYGN's description of GLP-1, GLP-2 and GIP pathways. | Independent proof of clinical outcomes or equivalence to prescription GLP-1 medicines. |
| ORYGN Real Science page | ORYGN's summary of ProGo research, regulatory notices, licensing and linked corporate announcements. | That every ProGo finding is a finished-triGLP clinical trial. |
| Hofseth BioCare material | Primary manufacturer information about ProGo, its production and regulatory activity. | Independent evaluation of ORYGN marketing or a medicine approval. |
| Published ingredient studies | Findings for the ingredient, population, dose and endpoints actually studied. | Guaranteed individual results or untested finished-product claims. |
What regulatory language means
ORYGN states that ProGo has a US New Dietary Ingredient notification and permitted structure/function claims. These concern dietary-supplement ingredients and claim notifications. They should not be described as FDA approval of triGLP for safety and effectiveness in the way a prescription medicine is approved.
The US National Institutes of Health explains that dietary supplements and medicines follow different regulatory pathways, and that supplements are not pre-approved for effectiveness like drugs.
Our publication standard
- Attribute ORYGN and manufacturer statements to their source.
- Identify whether a source concerns an ingredient or finished product.
- Avoid translating biomarker changes into guaranteed customer outcomes.
- Do not present triGLP as Ozempic, Wegovy or another prescription medicine.
- Update this guide when ORYGN publishes identifiable studies or revised product documentation.